Aditxt

Aditxt Shareholder Yield

The Shareholder Yield of Aditxt (ADTX) as of Nov 4, 2026 is 2,666.30 %. In the previous year, Shareholder Yield was 825.94 % — a change of 222.82% (higher).

Shareholder Yield

2,666.30 %

YoY

222.82%

Last updated:

Shareholder Yield of Aditxt is 2025 2,666.30 % . Shareholder Yield of Aditxt was 2024 825.94 % . It decreases by 222.82% higher compared to the previous year.

The Aditxt Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2018
182.81 USD
Jan 1, 2019
136.17 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
5.79 USD
Jan 1, 2023
0.29 USD
Jan 1, 2024
825.94 USD
Jan 1, 2025
2,666.30 USD
The Aditxt Shareholder Yield history
YEARShareholder YieldYoY
2,666.30 %+222.82%
825.94 %+285,087.10%
0.29 %-95.00%
5.79 %—
0.00—
0.00-100.00%
136.17 %-25.51%
182.81 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Shareholder Yield of Aditxt is 2,666.30 % in 2025.

Shareholder Yield of Aditxt changed from 825.94 % to 2,666.30 %, representing a 222.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield Aditxt since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's Aditxt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aditxt

All Key Metrics — Aditxt